PMID- 37711740
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230917
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Non-alcoholic fatty liver disease fibrosis score is a useful index for predicting 
      all-cause mortality in patients with antineutrophil cytoplasmic 
      antibody-associated vasculitis.
PG  - 1217937
LID - 10.3389/fmed.2023.1217937 [doi]
LID - 1217937
AB  - BACKGROUND: This study investigated whether the non-alcoholic fatty liver disease 
      fibrosis score (NFS) could predict all-cause mortality during follow-up among 
      patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). 
      METHODS: The medical records of 256 AAV patients were retrospectively reviewed. 
      AAV patients with clinically critical chronic liver diseases were excluded. NFS 
      was calculated using the following equation: NFS = -1.675 + 0.037 - age + 0.094 - 
      body mass index +1.13 x impaired fasting glucose/diabetes mellitus 
      +0.99 x aspartate aminotransferase/alanine aminotransferase ratio - 
      0.013 x platelet count - 0.66 x serum albumin. RESULTS: The median age was 
      59.0 years, and 35.2% of the patients were male. The median Birmingham Vasculitis 
      Activity Score (BVAS), five-factor score (FFS), and NFS were 12.0, 1.0, 
      and - 4.7, respectively. Of the 256 patients, 33 (12.9%) died. Using the receiver 
      operating characteristic curve, the optimal cut-off of NFS for all-cause 
      mortality was obtained as-3.97. AAV patients with NFS at diagnosis >/= - 3.97 
      exhibited a lower cumulative patients' survival rate than those with NFS at 
      diagnosis <-3.97. The multivariable Cox analysis revealed that NFS at diagnosis 
      >/= - 3.97 (HR 2.232, 95% CI 1.011, 4.925) was independently associated with 
      all-cause mortality in AAV patients. CONCLUSION: This study was the first to 
      demonstrate that NFS at AAV diagnosis was clinically useful in predicting 
      all-cause mortality during follow-up, regardless of both the degree of liver 
      fibrosis and abnormal or normal liver function results.
CI  - Copyright (c) 2023 Whang, Park, Park, Huh and Lee.
FAU - Whang, Jeong Yeop
AU  - Whang JY
AD  - Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Park, Pil Gyu
AU  - Park PG
AD  - Division of Rheumatology, Department of Internal Medicine, National Health 
      Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Huh, Ji Hye
AU  - Huh JH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym 
      University Sacred Heart Hospital, Anyang, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20230829
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10497776
OTO - NOTNLM
OT  - antineutrophil cytoplasmic antibody-associated vasculitis
OT  - fibrosis
OT  - mortality
OT  - non-alcoholic fatty liver disease
OT  - score
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/15 06:42
MHDA- 2023/09/15 06:43
PMCR- 2023/08/29
CRDT- 2023/09/15 03:57
PHST- 2023/05/06 00:00 [received]
PHST- 2023/08/16 00:00 [accepted]
PHST- 2023/09/15 06:43 [medline]
PHST- 2023/09/15 06:42 [pubmed]
PHST- 2023/09/15 03:57 [entrez]
PHST- 2023/08/29 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1217937 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Aug 29;10:1217937. doi: 10.3389/fmed.2023.1217937. 
      eCollection 2023.